Therapeutic Effect of Dupilumab on Systemic and Vascular Inflammation in Adults with Severe Atopic Dermatitis: Feasibility Study Using 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography
Keywords:Atopic dermatitis, Cardiovascular disease, Comorbidity, Dupilumab, Inflammation, PET/CT: positron emission tomography-computed tomography
Atopic dermatitis (AD) is an inflammatory skin disease associated with increased systemic and vascular inflammation. Although dupilumab has been proven to be effective against severe AD, imaging studies analysing its inflammation-reducing effect have rarely been reported. The aim of this study was to evaluate the effect of dupilumab on systemic and vascular inflammation in adult patients with severe AD, using 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT). A total of 33 adult patients with severe AD and 25 healthy controls underwent 18F-FDG PET/CT at baseline. Patients on dupilumab treatment underwent 18F-FDG PET/CT again after achieving a 75% reduction from baseline on the Eczema Area and Severity Index (EASI-75). Patients with AD exhibited increased 18F-FDG uptake values in the liver, spleen, pancreas, and carotid artery compared with healthy controls. However, compared with baseline, there was no statistically significant difference in 18F-FDG uptake in major organs and arteries after achieving EASI-75 with dupilumab treatment. In conclusion, while dupilumab treatment resulted in a significant clinical improvement and reduced serum inflammatory markers in adult patients with severe AD, no changes in systemic and vascular inflammation were observed on 18F-FDG PET/CT imaging.
Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol 2019; 123: 144-151.
https://doi.org/10.1016/j.anai.2019.04.020 DOI: https://doi.org/10.1016/j.anai.2019.04.020
Brunner PM, Silverberg JI, Guttman-Yassky E, Paller AS, Kabashima K, Amagai M, et al., Councilors of the International Eczema Council. increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol 2017; 137: 18-25.
https://doi.org/10.1016/j.jid.2016.08.022 DOI: https://doi.org/10.1016/j.jid.2016.08.022
Furue M, Kadono T. "Inflammatory skin march" in atopic dermatitis and psoriasis. Inflamm Res 2017; 66: 833-842.
https://doi.org/10.1007/s00011-017-1065-z DOI: https://doi.org/10.1007/s00011-017-1065-z
Kwa MC, Silverberg JI. Association between inflammatory skin disease, cardiovascular and cerebrovascular comorbidities in US adults: analysis of Nationwide Inpatient Sample data. Am J Clin Dermatol 2017; 18: 813-823.
https://doi.org/10.1007/s40257-017-0293-x DOI: https://doi.org/10.1007/s40257-017-0293-x
Vaidyanathan S, Patel CN, Scarsbrook AF, Chowdhury FU. FDG PET/CT in infection and inflammation - current and emerging clinical applications. Clin Radiol 2015; 70: 787-800.
https://doi.org/10.1016/j.crad.2015.03.010 DOI: https://doi.org/10.1016/j.crad.2015.03.010
Kim SJ, Park MY, Pak K, Han J, Kim GW, Kim HS, et al. Improvement of depressive symptoms in patients with moderate-to-severe psoriasis treated with ustekinumab: an open label trial validated using beck depression inventory, Hamilton depression rating scale measures and 18fluorodeoxyglucose (FDG) positron emission tomography (PET). J Dermatolog Treat 2018; 29: 761-768.
https://doi.org/10.1080/09546634.2018.1466021 DOI: https://doi.org/10.1080/09546634.2018.1466021
Lawal I, Sathekge M. F-18 FDG PET/CT imaging of cardiac and vascular inflammation and infection. Br Med Bull 2016; 120: 55-74.
https://doi.org/10.1093/bmb/ldw035 DOI: https://doi.org/10.1093/bmb/ldw035
Youn SW, Kang SY, Kim SA, Park GY, Lee WW. Subclinical systemic and vascular inflammation detected by (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with mild psoriasis. J Dermatol 2015; 42: 559-566.
https://doi.org/10.1111/1346-8138.12859 DOI: https://doi.org/10.1111/1346-8138.12859
Mehta NN, Yu Y, Saboury B, Foroughi N, Krishnamoorthy P, Raper A, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol 2011; 147: 1031-1039.
https://doi.org/10.1001/archdermatol.2011.119 DOI: https://doi.org/10.1001/archdermatol.2011.119
Kim BS, Lee WK, Pak K, Han J, Kim GW, Kim HS, et al. Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: feasibility study using 18F-fluorodeoxyglucose PET/CT. J Am Acad Dermatol 2019; 80: 1322-1331.
https://doi.org/10.1016/j.jaad.2018.03.011 DOI: https://doi.org/10.1016/j.jaad.2018.03.011
Ungar B, Pavel AB, Robson PM, Kaufman A, Pruzan A, Brunner P, et al. A preliminary 18F-FDG-PET/MRI study shows increased vascular inflammation in moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Pract 2020; 8: 3500-3506.
https://doi.org/10.1016/j.jaip.2020.07.018 DOI: https://doi.org/10.1016/j.jaip.2020.07.018
Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980; Suppl 92: 44-47.
https://doi.org/10.2340/00015555924447 DOI: https://doi.org/10.2340/00015555924447
Lee H, Kim BR, Kim KH, Lee DH, Na JI. One-year effectiveness and safety of dupilumab treatment for moderate-to-severe atopic dermatitis in Korean patients: a real-world retrospective analysis. Allergy Asthma Immunol Res 2022; 14: 117-122.
https://doi.org/10.4168/aair.2022.14.1.117 DOI: https://doi.org/10.4168/aair.2022.14.1.117
Guttman-Yassky E, Bissonnette R, Ungar B, Suárez-Fariñas M, Ardeleanu M, Esaki H, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol 2019; 143: 155-172.
https://doi.org/10.1016/j.jaci.2018.08.022 DOI: https://doi.org/10.1016/j.jaci.2018.08.022
Villani AP, Pavel AB, Wu J, Fernandes M, Maari C, Saint-Cyr Proulx E, et al. Vascular inflammation in moderate-to-severe atopic dermatitis is associated with enhanced Th2 response. Allergy 2021; 76: 3107-3121.
https://doi.org/10.1111/all.14859 DOI: https://doi.org/10.1111/all.14859
Rominger A, Saam T, Wolpers S, Cyran CC, Schmidt M, Foerster S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med 2009; 50: 1611-1620.
https://doi.org/10.2967/jnumed.109.065151 DOI: https://doi.org/10.2967/jnumed.109.065151
Elnabawi YA, Dey AK, Goyal A, Groenendyk JW, Chung JH, Belur AD, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res 2019; 115: 721-728.
https://doi.org/10.1093/cvr/cvz009 DOI: https://doi.org/10.1093/cvr/cvz009
Kim JD, Lee SH, Seo EH, Woo SY, Kim SH, Chung SM, et al. Role of Th1 and Th17 cells in the development and complexity of coronary artery disease: comparison analysis by the methods of flow cytometry and SYNTAX score. Coron Artery Dis 2015; 26: 604-611.
https://doi.org/10.1097/MCA.0000000000000289 DOI: https://doi.org/10.1097/MCA.0000000000000289
Taleb S. Inflammation in atherosclerosis. Arch Cardiovasc Dis 2016; 109: 708-715.
https://doi.org/10.1016/j.acvd.2016.04.002 DOI: https://doi.org/10.1016/j.acvd.2016.04.002
Radtke MA, Schäfer I, Glaeske G, Jacobi A, Augustin M. Prevalence and comorbidities in adults with psoriasis compared to atopic eczema. J Eur Acad Dermatol Venereol 2017; 31: 151-157.
https://doi.org/10.1111/jdv.13813 DOI: https://doi.org/10.1111/jdv.13813
Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol 2004; 44: 1945-1956.
https://doi.org/10.1016/j.jacc.2004.07.056 DOI: https://doi.org/10.1016/j.jacc.2004.07.056
Vekaria AS, Brunner PM, Aleisa AI, Bonomo L, Lebwohl MG, Israel A, et al. Moderate-to-severe atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity. F1000Res 2017; 6: 1712.
https://doi.org/10.12688/f1000research.12422.2 DOI: https://doi.org/10.12688/f1000research.12422.2
How to Cite
Copyright (c) 2023 Gi-Wook Lee, Keunyoung Kim, Seong-Jang Kim, Kihyuk Shin, Hoonsoo Kim, Hyun-Chang Ko, Moon-Bum Kim, Byungsoo Kim
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.